NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|2039143|gb|AAB52971|]
View 

aminopeptidase B [Rattus norvegicus]

Protein Classification

M1 family metallopeptidase( domain architecture ID 10176143)

M1 family metallopeptidase is a zinc-dependent metallopeptidase that functions as an aminopeptidase and contains an HEXXH motif as part of its active site; such as aminopeptidase B that selectively removes arginine and/or lysine residues from the N-terminus of peptide substrates

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
24-482 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


:

Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 636.42  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143   24 DVASASSFRAFEILHLHLDLRAELPpgpgpgSRGLNGKATLELRCLlPEGASELRLDShSCLEVMAATLlrgqpgdqqQL 103
Cdd:cd09599   1 DPSSFSNYDEVRTTHLDLDLTVDFD------KKTISGSATLTLEVL-QDGADELVLDT-RDLDISSVTV---------NG 63
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  104 TEPVPFHTQPFS-HYGQALCVVFPKPCCAAERFRLELTYRVGEG-PGVCWLAPEQTAGKKKPFVYTQGQAVLNRAFFPCF 181
Cdd:cd09599  64 GKELKFELGPRDpVLGSALTITLPSPLAKGDTFKVKIEYSTTPQaTALQWLTPEQTAGKKHPYLFTQCQAIHARSLFPCQ 143
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  182 DTPAVKCTYSALVEVPDGFTAVMSASTWERR---GPNKFFFQMSQPIPSYLIALAIGDLASAEVGPRSRV-TEPCLIEAA 257
Cdd:cd09599 144 DTPSVKSTYSATVTVPKGLTALMSALRTGEKeeaGTGTYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVwAEPSVVDAA 223
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  258 KEEYnGVIEEFLATGEKLFGPYVWGRYDLLFMPPSFPFGGMENPCLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTNA 337
Cdd:cd09599 224 AEEF-ADTEKFLKAAEKLYGPYVWGRYDLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTNA 302
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  338 NWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDVSGEENPLNKLrVKIEPGVDPDDTYNETPYEKGYC 417
Cdd:cd09599 303 NWEHFWLNEGFTVYLERRILERLYGEEYRQFEAILGWKDLQESIKEFGEDPPYTLL-VPDLKGVDPDDAFSSVPYEKGFQ 381
                       410       420       430       440       450       460
                ....*....|....*....|....*....|....*....|....*....|....*....|....*
gi 2039143  418 FVSYLAHLVGdQEQFDKFLKAYVDEFKFQSILAEDFLEFYLEYFPELKKKGVDSIpgfEFNRWLN 482
Cdd:cd09599 382 FLYYLEQLGG-REVFDPFLRAYFKKFAFQSIDTEDFKDFLLEYFAEDKPEILDKI---DWDAWLY 442
Leuk-A4-hydro_C pfam09127
Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of ...
528-643 6.55e-40

Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of two layers of parallel alpha-helices, five in the inner layer and four in the outer, arranged in an antiparallel manner, with perpendicular loops containing short helical segments on top. They are required for the formation of a deep cleft harbouring the catalytic Zn2+ site in Leukotriene A4 hydrolase.


:

Pssm-ID: 462686  Cd Length: 112  Bit Score: 141.86  E-value: 6.55e-40
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    528 WKTYQLVYFLDKILQKSPLPPGNVKKLGETYpKISNAQNAELRLRWGQIILKNDHQEEFWKVKDFLQSQGKQKYTLPLYH 607
Cdd:pfam09127   1 WSSNQKVVFLERLLEFSPLSPEQLKALDEVY-KLSESKNAEIRFRWLRLALKAKYEPAYPEVAEFLGEVGRMKFVRPLYR 79
                          90       100       110
                  ....*....|....*....|....*....|....*.
gi 2039143    608 AMMGGSemaRTLAKETFSATASQLHSNVVNYVQQIL 643
Cdd:pfam09127  80 ALNKVD---RDLAVETFEKNKDFYHPICRAMVEKDL 112
 
Name Accession Description Interval E-value
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
24-482 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 636.42  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143   24 DVASASSFRAFEILHLHLDLRAELPpgpgpgSRGLNGKATLELRCLlPEGASELRLDShSCLEVMAATLlrgqpgdqqQL 103
Cdd:cd09599   1 DPSSFSNYDEVRTTHLDLDLTVDFD------KKTISGSATLTLEVL-QDGADELVLDT-RDLDISSVTV---------NG 63
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  104 TEPVPFHTQPFS-HYGQALCVVFPKPCCAAERFRLELTYRVGEG-PGVCWLAPEQTAGKKKPFVYTQGQAVLNRAFFPCF 181
Cdd:cd09599  64 GKELKFELGPRDpVLGSALTITLPSPLAKGDTFKVKIEYSTTPQaTALQWLTPEQTAGKKHPYLFTQCQAIHARSLFPCQ 143
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  182 DTPAVKCTYSALVEVPDGFTAVMSASTWERR---GPNKFFFQMSQPIPSYLIALAIGDLASAEVGPRSRV-TEPCLIEAA 257
Cdd:cd09599 144 DTPSVKSTYSATVTVPKGLTALMSALRTGEKeeaGTGTYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVwAEPSVVDAA 223
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  258 KEEYnGVIEEFLATGEKLFGPYVWGRYDLLFMPPSFPFGGMENPCLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTNA 337
Cdd:cd09599 224 AEEF-ADTEKFLKAAEKLYGPYVWGRYDLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTNA 302
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  338 NWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDVSGEENPLNKLrVKIEPGVDPDDTYNETPYEKGYC 417
Cdd:cd09599 303 NWEHFWLNEGFTVYLERRILERLYGEEYRQFEAILGWKDLQESIKEFGEDPPYTLL-VPDLKGVDPDDAFSSVPYEKGFQ 381
                       410       420       430       440       450       460
                ....*....|....*....|....*....|....*....|....*....|....*....|....*
gi 2039143  418 FVSYLAHLVGdQEQFDKFLKAYVDEFKFQSILAEDFLEFYLEYFPELKKKGVDSIpgfEFNRWLN 482
Cdd:cd09599 382 FLYYLEQLGG-REVFDPFLRAYFKKFAFQSIDTEDFKDFLLEYFAEDKPEILDKI---DWDAWLY 442
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
24-632 3.52e-172

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 503.93  E-value: 3.52e-172
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143     24 DVASASSFRAFEILHLHLDLRAELPpgpgpgSRGLNGKATLELRCLLPEGASeLRLDShSCLEVMAATLLrGQPGDQQqL 103
Cdd:TIGR02411   1 DPSSLSNYKDFRTSHTDLNLSVDFT------KRKLSGSVTFTLKSLTDNLNK-LVLDT-SYLDIQKVTIN-GLPADFA-I 70
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    104 TEPVPFhtqpfshYGQALCVVFPKPCCAAERFRLELTYRVGEG-PGVCWLAPEQTAGKKKPFVYTQGQAVLNRAFFPCFD 182
Cdd:TIGR02411  71 GERKEP-------LGSPLTISLPIATSKNDEFVLNISFSTTPKcTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPCQD 143
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    183 TPAVKCTYSALVEVPdgFTAVMSASTWER--RGPNKFFFQMSQPIPSYLIALAIGDLASAEVGPRSRV-TEPCLIEAAKE 259
Cdd:TIGR02411 144 TPSVKSTYTAEVESP--LPVLMSGIRDGEtsNDPGKYLFKQKVPIPAYLIAIASGDLASAPIGPRSTVySEPEQLEKCQY 221
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    260 EYNGVIEEFLATGEKLFGPYVWGRYDLLFMPPSFPFGGMENPCLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTNANW 339
Cdd:TIGR02411 222 EFENDTEKFIKTAEDLIFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSW 301
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    340 GEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDVSGEENPLNKLRVKIEPGvDPDDTYNETPYEKGYCFV 419
Cdd:TIGR02411 302 EHFWLNEGWTVYLERRIIGRLYGEKTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDN-DPDDAFSSVPYEKGFNFL 380
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    420 SYLAHLVGDQEQFDKFLKAYVDEFKFQSILAEDFLEFYLEYFPELKKkgVDSIPGFEFNRWLNTPGWPPYLPDLSPgdSL 499
Cdd:TIGR02411 381 FYLEQLLGGPAEFDPFLRHYFKKFAYKSLDTYQFKDALYEYFKDKKK--VDKLDAVDWETWLYSPGMPPVKPNFDT--TL 456
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    500 MKPAEELAELW--AASEPDMQAIEAVAISTWKTYQLVYFLDKILQKS---PLPPGNVKKLGETYPkISNAQNAELRLRWG 574
Cdd:TIGR02411 457 ADECYALADRWvdAAKADDLSSFNAKDIKDFSSHQLVLFLETLTERGgdwALPEGHIKRLGDIYN-FAASKNAEVRFRWF 535
                         570       580       590       600       610
                  ....*....|....*....|....*....|....*....|....*....|....*...
gi 2039143    575 QIILKNDHQEEFWKVKDFLQSQGKQKYTLPLYHAMmgGSEMARTLAKETFSATASQLH 632
Cdd:TIGR02411 536 RLAIQAKLEDEYPLLADWLGTVGRMKFVRPGYRLL--NAFVDRDLAIRTFEKFKDSYH 591
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
32-494 7.42e-88

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 286.15  E-value: 7.42e-88
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143   32 RAFEILHLHLDLRaelppgPGPGSRGLNGKATLELRCLLPeGASELRLDSHScLEVMAATLlrgqpgDQQQLtepvpfht 111
Cdd:COG0308  13 PGYDVTHYDLDLD------LDPATTRLSGTATITFTATEA-PLDSLVLDLKG-LEVTSVTV------DGKPL-------- 70
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  112 qPFSHYGQALCVVFPKPCCAAERFRLELTYRV-----GEGpgvcwLAPEQTAGKKKPFVYTQGQAVLNRAFFPCFDTPAV 186
Cdd:COG0308  71 -DFTRDGERLTITLPKPLAPGETFTLEIEYSGkpsngGEG-----LYRSGDPPDGPPYLYTQCEPEGARRWFPCFDHPDD 144
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  187 KCTYSALVEVPDGFTAVMSA---STWERRGPNKFF-FQMSQPIPSYLIALAIGDLASAEVGPRSRV-----TEPCLIEAA 257
Cdd:COG0308 145 KATFTLTVTVPAGWVAVSNGnlvSETELGDGRTTWhWADTQPIPTYLFALAAGDYAVVEDTFASGVplrvyVRPGLADKA 224
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  258 KEEYnGVIEEFLATGEKLFG-PYVWGRYDLLFMPpSFPFGGMENPCLTFVTPCLLAGDR-------SLADVIIHEISHSW 329
Cdd:COG0308 225 KEAF-ESTKRMLDFFEELFGvPYPFDKYDQVAVP-DFNFGAMENQGLVTFGEKVLADETatdadyeRRESVIAHELAHQW 302
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  330 FGNLVTNANWGEFWLNEGFTMYAQRRISTILFGAAytclEAATGRALLRQHMDVSGEENPlNKLRVKIEPGVDPDDTYNE 409
Cdd:COG0308 303 FGNLVTCADWDDLWLNEGFATYMEQLFSEDLYGKD----AADRIFVGALRSYAFAEDAGP-NAHPIRPDDYPEIENFFDG 377
                       410       420       430       440       450       460       470       480
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  410 TPYEKGYCFVSYLAHLVGDqEQFDKFLKAYVDEFKFQSILAEDFLEfYLEyfpelKKKGVDSipGFEFNRWLNTPGWPPY 489
Cdd:COG0308 378 IVYEKGALVLHMLRTLLGD-EAFRAGLRLYFARHAGGNATTEDFLA-ALE-----EASGRDL--SAFFDQWLYQAGLPTL 448

                ....*
gi 2039143  490 LPDLS 494
Cdd:COG0308 449 EVEYE 453
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
260-480 1.43e-68

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 222.55  E-value: 1.43e-68
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    260 EYNGVIEEFLATGEKLFGPYVWGRYDLLFMPpSFPFGGMENPCLTFVTPCLLAGD---------RSLADVIIHEISHSWF 330
Cdd:pfam01433   2 ALEITVKLLEFYEDYFNIPYPLPKYDLVALP-DFSAGAMENWGLITYRETLLLYDpgnsstsdkQRVASVIAHELAHQWF 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    331 GNLVTNANWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDVSGEENPLNklrVKIEPGVDPDDTYNET 410
Cdd:pfam01433  81 GNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPIT---QNVNDPSEIDDIFDAI 157
                         170       180       190       200       210       220       230
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    411 PYEKGYCFVSYLAHLVGDqEQFDKFLKAYVDEFKFQSILAEDFLEFYLEYfpeLKKKGVDSIpgfeFNRW 480
Cdd:pfam01433 158 PYEKGASVLRMLETLLGE-EVFQKGLRSYLKKFQYGNATTEDLWDALSEA---SGPLDVDSF----MDTW 219
Leuk-A4-hydro_C pfam09127
Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of ...
528-643 6.55e-40

Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of two layers of parallel alpha-helices, five in the inner layer and four in the outer, arranged in an antiparallel manner, with perpendicular loops containing short helical segments on top. They are required for the formation of a deep cleft harbouring the catalytic Zn2+ site in Leukotriene A4 hydrolase.


Pssm-ID: 462686  Cd Length: 112  Bit Score: 141.86  E-value: 6.55e-40
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    528 WKTYQLVYFLDKILQKSPLPPGNVKKLGETYpKISNAQNAELRLRWGQIILKNDHQEEFWKVKDFLQSQGKQKYTLPLYH 607
Cdd:pfam09127   1 WSSNQKVVFLERLLEFSPLSPEQLKALDEVY-KLSESKNAEIRFRWLRLALKAKYEPAYPEVAEFLGEVGRMKFVRPLYR 79
                          90       100       110
                  ....*....|....*....|....*....|....*.
gi 2039143    608 AMMGGSemaRTLAKETFSATASQLHSNVVNYVQQIL 643
Cdd:pfam09127  80 ALNKVD---RDLAVETFEKNKDFYHPICRAMVEKDL 112
 
Name Accession Description Interval E-value
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
24-482 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 636.42  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143   24 DVASASSFRAFEILHLHLDLRAELPpgpgpgSRGLNGKATLELRCLlPEGASELRLDShSCLEVMAATLlrgqpgdqqQL 103
Cdd:cd09599   1 DPSSFSNYDEVRTTHLDLDLTVDFD------KKTISGSATLTLEVL-QDGADELVLDT-RDLDISSVTV---------NG 63
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  104 TEPVPFHTQPFS-HYGQALCVVFPKPCCAAERFRLELTYRVGEG-PGVCWLAPEQTAGKKKPFVYTQGQAVLNRAFFPCF 181
Cdd:cd09599  64 GKELKFELGPRDpVLGSALTITLPSPLAKGDTFKVKIEYSTTPQaTALQWLTPEQTAGKKHPYLFTQCQAIHARSLFPCQ 143
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  182 DTPAVKCTYSALVEVPDGFTAVMSASTWERR---GPNKFFFQMSQPIPSYLIALAIGDLASAEVGPRSRV-TEPCLIEAA 257
Cdd:cd09599 144 DTPSVKSTYSATVTVPKGLTALMSALRTGEKeeaGTGTYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVwAEPSVVDAA 223
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  258 KEEYnGVIEEFLATGEKLFGPYVWGRYDLLFMPPSFPFGGMENPCLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTNA 337
Cdd:cd09599 224 AEEF-ADTEKFLKAAEKLYGPYVWGRYDLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTNA 302
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  338 NWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDVSGEENPLNKLrVKIEPGVDPDDTYNETPYEKGYC 417
Cdd:cd09599 303 NWEHFWLNEGFTVYLERRILERLYGEEYRQFEAILGWKDLQESIKEFGEDPPYTLL-VPDLKGVDPDDAFSSVPYEKGFQ 381
                       410       420       430       440       450       460
                ....*....|....*....|....*....|....*....|....*....|....*....|....*
gi 2039143  418 FVSYLAHLVGdQEQFDKFLKAYVDEFKFQSILAEDFLEFYLEYFPELKKKGVDSIpgfEFNRWLN 482
Cdd:cd09599 382 FLYYLEQLGG-REVFDPFLRAYFKKFAFQSIDTEDFKDFLLEYFAEDKPEILDKI---DWDAWLY 442
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
24-632 3.52e-172

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 503.93  E-value: 3.52e-172
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143     24 DVASASSFRAFEILHLHLDLRAELPpgpgpgSRGLNGKATLELRCLLPEGASeLRLDShSCLEVMAATLLrGQPGDQQqL 103
Cdd:TIGR02411   1 DPSSLSNYKDFRTSHTDLNLSVDFT------KRKLSGSVTFTLKSLTDNLNK-LVLDT-SYLDIQKVTIN-GLPADFA-I 70
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    104 TEPVPFhtqpfshYGQALCVVFPKPCCAAERFRLELTYRVGEG-PGVCWLAPEQTAGKKKPFVYTQGQAVLNRAFFPCFD 182
Cdd:TIGR02411  71 GERKEP-------LGSPLTISLPIATSKNDEFVLNISFSTTPKcTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPCQD 143
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    183 TPAVKCTYSALVEVPdgFTAVMSASTWER--RGPNKFFFQMSQPIPSYLIALAIGDLASAEVGPRSRV-TEPCLIEAAKE 259
Cdd:TIGR02411 144 TPSVKSTYTAEVESP--LPVLMSGIRDGEtsNDPGKYLFKQKVPIPAYLIAIASGDLASAPIGPRSTVySEPEQLEKCQY 221
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    260 EYNGVIEEFLATGEKLFGPYVWGRYDLLFMPPSFPFGGMENPCLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTNANW 339
Cdd:TIGR02411 222 EFENDTEKFIKTAEDLIFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSW 301
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    340 GEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDVSGEENPLNKLRVKIEPGvDPDDTYNETPYEKGYCFV 419
Cdd:TIGR02411 302 EHFWLNEGWTVYLERRIIGRLYGEKTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDN-DPDDAFSSVPYEKGFNFL 380
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    420 SYLAHLVGDQEQFDKFLKAYVDEFKFQSILAEDFLEFYLEYFPELKKkgVDSIPGFEFNRWLNTPGWPPYLPDLSPgdSL 499
Cdd:TIGR02411 381 FYLEQLLGGPAEFDPFLRHYFKKFAYKSLDTYQFKDALYEYFKDKKK--VDKLDAVDWETWLYSPGMPPVKPNFDT--TL 456
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    500 MKPAEELAELW--AASEPDMQAIEAVAISTWKTYQLVYFLDKILQKS---PLPPGNVKKLGETYPkISNAQNAELRLRWG 574
Cdd:TIGR02411 457 ADECYALADRWvdAAKADDLSSFNAKDIKDFSSHQLVLFLETLTERGgdwALPEGHIKRLGDIYN-FAASKNAEVRFRWF 535
                         570       580       590       600       610
                  ....*....|....*....|....*....|....*....|....*....|....*...
gi 2039143    575 QIILKNDHQEEFWKVKDFLQSQGKQKYTLPLYHAMmgGSEMARTLAKETFSATASQLH 632
Cdd:TIGR02411 536 RLAIQAKLEDEYPLLADWLGTVGRMKFVRPGYRLL--NAFVDRDLAIRTFEKFKDSYH 591
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
37-456 2.07e-88

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 281.64  E-value: 2.07e-88
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143   37 LHLHLDLRaelppgpgPGSRGLNGKATLELRCllPEGASELRLDSHScLEV-------MAATLLRGQPGDQQQLTEPVPF 109
Cdd:cd09595   3 YDLDLDVD--------FTTKTLNGTETLTVDA--SQVGRELVLDLVG-LTIhsvsvngAAVDFGEREHYDGEKLTIPGPK 71
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  110 htqpfshygqalcvvfPKPccaaERFRLELTYRVGE---GPGVCWlapEQTAGKKKPFVYTQGQAVLNRAFFPCFDTPAV 186
Cdd:cd09595  72 ----------------PPG----QTFTVRISFEAKPsknLLGWLW---EQTAGKEKPYLFTQFEATHARRIFPCIDHPAV 128
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  187 KCTYSALVEVPDGFT-AVMSASTWERRGPNK---FFFQMSQPIPSYLIALAIGDLASAEVGPRSRVTEPCLIEAAKEEYN 262
Cdd:cd09595 129 KATFTVTITTPKKDLlASNGALVGEETGANGrktYRFEDTPPIPTYLVAVVVGDLEFKYVTVKSQPRVGLSVYSEPLQVD 208
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  263 GVIEEF------LATGEKLFG-PYVWGRYDLLfMPPSFPFGGMENPCLTFVTPCLLA-------GDRSLADVIIHEISHS 328
Cdd:cd09595 209 QAQYAFdatraaLAWFEDYFGgPYPLPKYDLL-AVPDFNSGAMENPGLITFRTTYLLrskvtdtGARSIENVIAHELAHQ 287
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  329 WFGNLVTNANWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDVSGEENPLnklrVKIEPGVDPDDTYN 408
Cdd:cd09595 288 WFGNLVTMRWWNDLWLNEGFAVYYENRIMDATFGTSSRHLDQLSGSSDLNTEQLLEDSSPTS----TPVRSPADPDVAYD 363
                       410       420       430       440
                ....*....|....*....|....*....|....*....|....*...
gi 2039143  409 ETPYEKGYCFVSYLAHLVGDqEQFDKFLKAYVDEFKFQSILAEDFLEF 456
Cdd:cd09595 364 GVTYAKGALVLRMLEELVGE-EAFDKGVQAYFNRHKFKNATTDDFIDA 410
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
32-494 7.42e-88

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 286.15  E-value: 7.42e-88
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143   32 RAFEILHLHLDLRaelppgPGPGSRGLNGKATLELRCLLPeGASELRLDSHScLEVMAATLlrgqpgDQQQLtepvpfht 111
Cdd:COG0308  13 PGYDVTHYDLDLD------LDPATTRLSGTATITFTATEA-PLDSLVLDLKG-LEVTSVTV------DGKPL-------- 70
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  112 qPFSHYGQALCVVFPKPCCAAERFRLELTYRV-----GEGpgvcwLAPEQTAGKKKPFVYTQGQAVLNRAFFPCFDTPAV 186
Cdd:COG0308  71 -DFTRDGERLTITLPKPLAPGETFTLEIEYSGkpsngGEG-----LYRSGDPPDGPPYLYTQCEPEGARRWFPCFDHPDD 144
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  187 KCTYSALVEVPDGFTAVMSA---STWERRGPNKFF-FQMSQPIPSYLIALAIGDLASAEVGPRSRV-----TEPCLIEAA 257
Cdd:COG0308 145 KATFTLTVTVPAGWVAVSNGnlvSETELGDGRTTWhWADTQPIPTYLFALAAGDYAVVEDTFASGVplrvyVRPGLADKA 224
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  258 KEEYnGVIEEFLATGEKLFG-PYVWGRYDLLFMPpSFPFGGMENPCLTFVTPCLLAGDR-------SLADVIIHEISHSW 329
Cdd:COG0308 225 KEAF-ESTKRMLDFFEELFGvPYPFDKYDQVAVP-DFNFGAMENQGLVTFGEKVLADETatdadyeRRESVIAHELAHQW 302
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  330 FGNLVTNANWGEFWLNEGFTMYAQRRISTILFGAAytclEAATGRALLRQHMDVSGEENPlNKLRVKIEPGVDPDDTYNE 409
Cdd:COG0308 303 FGNLVTCADWDDLWLNEGFATYMEQLFSEDLYGKD----AADRIFVGALRSYAFAEDAGP-NAHPIRPDDYPEIENFFDG 377
                       410       420       430       440       450       460       470       480
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  410 TPYEKGYCFVSYLAHLVGDqEQFDKFLKAYVDEFKFQSILAEDFLEfYLEyfpelKKKGVDSipGFEFNRWLNTPGWPPY 489
Cdd:COG0308 378 IVYEKGALVLHMLRTLLGD-EAFRAGLRLYFARHAGGNATTEDFLA-ALE-----EASGRDL--SAFFDQWLYQAGLPTL 448

                ....*
gi 2039143  490 LPDLS 494
Cdd:COG0308 449 EVEYE 453
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
260-480 1.43e-68

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 222.55  E-value: 1.43e-68
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    260 EYNGVIEEFLATGEKLFGPYVWGRYDLLFMPpSFPFGGMENPCLTFVTPCLLAGD---------RSLADVIIHEISHSWF 330
Cdd:pfam01433   2 ALEITVKLLEFYEDYFNIPYPLPKYDLVALP-DFSAGAMENWGLITYRETLLLYDpgnsstsdkQRVASVIAHELAHQWF 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    331 GNLVTNANWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDVSGEENPLNklrVKIEPGVDPDDTYNET 410
Cdd:pfam01433  81 GNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPIT---QNVNDPSEIDDIFDAI 157
                         170       180       190       200       210       220       230
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    411 PYEKGYCFVSYLAHLVGDqEQFDKFLKAYVDEFKFQSILAEDFLEFYLEYfpeLKKKGVDSIpgfeFNRW 480
Cdd:pfam01433 158 PYEKGASVLRMLETLLGE-EVFQKGLRSYLKKFQYGNATTEDLWDALSEA---SGPLDVDSF----MDTW 219
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
34-456 2.53e-66

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 223.23  E-value: 2.53e-66
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143   34 FEILHLHLDLRAELPpgpgpgSRGLNGKATLELRCLlpEGASELRLDSHScLEVMAATLlrgqpgDQQqltePVPFhtqp 113
Cdd:cd09603   1 YDVLHYDLDLDYDPA------TKSLSGTATITFRAT--QDLDSLQLDLVG-LTVSSVTV------DGV----PAAF---- 57
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  114 FSHYGQALCVVFPKPCCAAERFRLELTY----RVGEGPGvcWLAPEQTAGKkkPFVYTQGQAVLNRAFFPCFDTPAVKCT 189
Cdd:cd09603  58 FTHDGDKLVITLPRPLAAGETFTVTVRYsgkpRPAGYPP--GDGGGWEEGD--DGVWTAGQPEGASTWFPCNDHPDDKAT 133
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  190 YSALVEVPDGFTAV---MSASTWERRGPNK-FFFQMSQPIPSYLIALAIGDLASAEVGPRSRVT-----EPCLIEAAKEE 260
Cdd:cd09603 134 YDITVTVPAGLTVVsngRLVSTTTNGGGTTtWHWKMDYPIATYLVTLAVGRYAVVEDGSGGGIPlryyvPPGDAAKAKAS 213
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  261 YNGVIE--EFLatgEKLFGPYVWGRYDLLFMPPSFpfGGMENPCLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTNAN 338
Cdd:cd09603 214 FARTPEmlDFF---EELFGPYPFEKYGQVVVPDLG--GGMEHQTATTYGNNFLNGDRGSERLIAHELAHQWFGDSVTCAD 288
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  339 WGEFWLNEGFTMYAQrristilfgAAYTclEAATGRALLRQHMdvSGEENPLNKLRVKIEPGVDPDDTYNETPYEKGYCF 418
Cdd:cd09603 289 WADIWLNEGFATYAE---------WLWS--EHKGGADAYRAYL--AGQRQDYLNADPGPGRPPDPDDLFDRDVYQKGALV 355
                       410       420       430
                ....*....|....*....|....*....|....*...
gi 2039143  419 VSYLAHLVGDqEQFDKFLKAYVDEFKFQSILAEDFLEF 456
Cdd:cd09603 356 LHMLRNLLGD-EAFFAALRAYLARYAHGNVTTEDFIAA 392
Leuk-A4-hydro_C pfam09127
Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of ...
528-643 6.55e-40

Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of two layers of parallel alpha-helices, five in the inner layer and four in the outer, arranged in an antiparallel manner, with perpendicular loops containing short helical segments on top. They are required for the formation of a deep cleft harbouring the catalytic Zn2+ site in Leukotriene A4 hydrolase.


Pssm-ID: 462686  Cd Length: 112  Bit Score: 141.86  E-value: 6.55e-40
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    528 WKTYQLVYFLDKILQKSPLPPGNVKKLGETYpKISNAQNAELRLRWGQIILKNDHQEEFWKVKDFLQSQGKQKYTLPLYH 607
Cdd:pfam09127   1 WSSNQKVVFLERLLEFSPLSPEQLKALDEVY-KLSESKNAEIRFRWLRLALKAKYEPAYPEVAEFLGEVGRMKFVRPLYR 79
                          90       100       110
                  ....*....|....*....|....*....|....*.
gi 2039143    608 AMMGGSemaRTLAKETFSATASQLHSNVVNYVQQIL 643
Cdd:pfam09127  80 ALNKVD---RDLAVETFEKNKDFYHPICRAMVEKDL 112
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
159-482 5.38e-39

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 149.27  E-value: 5.38e-39
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  159 GKKKPFVYTQGQAVLNRAFFPCFDTPAVKCTYSALVEVPDGFTAV--MSA--STWERRGPNKFFFQMSQPIPSYLIALAI 234
Cdd:cd09601 110 GETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTALsnMPPveSTELEDGWKTTTFETTPPMSTYLVAFVV 189
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  235 GDLASAEVGPRSRV-----TEPCLIEAAKE--EYNGVIEEFLatgEKLFG-PYVwgrydllfMP-------PSFPFGGME 299
Cdd:cd09601 190 GDFEYIESTTKSGVpvrvyARPGKIEQGDFalEVAPKILDFY---EDYFGiPYP--------LPkldlvaiPDFAAGAME 258
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  300 NP-CLTFVTPCLLAGD--------RSLADVIIHEISHSWFGNLVTNANWGEFWLNEGFTMYAQRristilFGAAYTCLE- 369
Cdd:cd09601 259 NWgLITYRETALLYDPktssasdkQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGFATYMEY------LAVDKLFPEw 332
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  370 --------AATGRALlrqHMDVSGEENPlnkLRVKIEPGVDPDDTYNETPYEKGYCFVSYLAHLVGDqEQFDKFLKAYVD 441
Cdd:cd09601 333 nmwdqfvvDELQSAL---ELDSLASSHP---IEVPVESPSEISEIFDAISYSKGASVLRMLENFLGE-EVFRKGLRKYLK 405
                       330       340       350       360
                ....*....|....*....|....*....|....*....|.
gi 2039143  442 EFKFQSILAEDFLEFYLEYFPELKKKGVDSIpgfeFNRWLN 482
Cdd:cd09601 406 KHAYGNATTDDLWEALQEASGESKPLDVKEI----MDSWTL 442
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
161-455 4.56e-33

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 132.25  E-value: 4.56e-33
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  161 KKPFVYTQGqaVLNRA--FFPCFDTPAVKCTYSALVEVPDGFTAV---MSASTWERRGPNKFFFQMSQPIPSYLIALAIG 235
Cdd:cd09602 114 GETYLYTLF--EPDDArrVFPCFDQPDLKATFTLTVTAPADWTVIsngPETSTEEAGGRKRWRFAETPPLSTYLFAFVAG 191
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  236 DLASAEvGPRSRVTEPCLIEAAKEEYNGVIEE-FLATG------EKLFG-PYVWGRYDLLFMPpSFPFGGMENP-CLTF- 305
Cdd:cd09602 192 PYHRVE-DEHDGIPLGLYCRESLAEYERDADEiFEVTKqgldfyEDYFGiPYPFGKYDQVFVP-EFNFGAMENPgAVTFr 269
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  306 --------VTPCLLAGdrsLADVIIHEISHSWFGNLVTNANWGEFWLNEGFTMYaqrristilfgAAYTCLEAATGrall 377
Cdd:cd09602 270 esylfreePTRAQRLR---RANTILHEMAHMWFGDLVTMKWWDDLWLNESFADF-----------MAAKALAEATP---- 331
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  378 rqhmdvsGEENPLNKLRVKIEPGVDPDDTYNETP-------------------YEKGYCFVSYLAHLVGDqEQFDKFLKA 438
Cdd:cd09602 332 -------FTDAWLTFLLRRKPWAYRADQLPTTHPiaqdvpdleaagsnfdgitYAKGASVLKQLVALVGE-EAFRAGLRE 403
                       330
                ....*....|....*..
gi 2039143  439 YVDEFKFQSILAEDFLE 455
Cdd:cd09602 404 YFKKHAYGNATLDDLIA 420
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
162-454 4.06e-27

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 117.20  E-value: 4.06e-27
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    162 KPFVYTQGQAVLNRAFFPCFDTPAVKCTYSALVEVPDGFTaVMSASTWE----RRGPNKFFFQMSQPIPSYLIALAIGDL 237
Cdd:TIGR02412 117 EVYLYTQFEPADARRVFAVFDQPDLKANFKFSVKAPEDWT-VISNSRETdvtpEPADRRWEFPETPKLSTYLTAVAAGPY 195
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    238 ASAEVGPRSRvtePCLIEAAK--------EEYNGVIEEFLATGEKLFG-PYVWGRYDLLFMPpSFPFGGMENP-CLTF-- 305
Cdd:TIGR02412 196 HSVQDESRSY---PLGIYARRslaqyldaDAIFTITRQGLAFFHRKFGyPYPFKKYDQIFVP-EFNAGAMENAgCVTFae 271
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    306 -------VTPCLLAGdrsLADVIIHEISHSWFGNLVTNANWGEFWLNEGFTMYAQRRISTilfgAAYTCLEAATGRALLR 378
Cdd:TIGR02412 272 nflhraeATRAEKEN---RAGVILHEMAHMWFGDLVTMRWWNDLWLNESFAEYMGTLASA----EATEYTDAWTTFAAQG 344
                         250       260       270       280       290       300       310
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 2039143    379 QHMDVSGEENPL-NKLRVKIEPGVDPDDTYNETPYEKGYCFVSYLAHLVGDqEQFDKFLKAYVDEFKFQSILAEDFL 454
Cdd:TIGR02412 345 KQWAYEADQLPTtHPIVADVADLADALSNFDGITYAKGASVLKQLVAWVGE-EAFFAGVNAYFKRHAFGNATLDDLI 420
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
255-456 1.18e-25

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 110.44  E-value: 1.18e-25
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  255 EAAKEEYNGVIEEFLATGEKLFGPYVWGRYDLLFMPpsFPFGGMENPCLTFVTPCLLAGDRSLADVIIHEISHSWFGNLV 334
Cdd:cd09604 233 AEAAERALEYAKDALEFFSEKFGPYPYPELDVVQGP--FGGGGMEYPGLVFIGSRLYDPKRSLEGVVVHEIAHQWFYGIV 310
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  335 TN--ANWGefWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDVSGEENPLNKLrvkiepgvDPDDTYNETPY 412
Cdd:cd09604 311 GNdeRREP--WLDEGLATYAESLYLEEKYGKEAADELLGRRYYRAYARGPGGPINLPLDTF--------PDGSYYSNAVY 380
                       170       180       190       200
                ....*....|....*....|....*....|....*....|....
gi 2039143  413 EKGYCFVSYLAHLVGDqEQFDKFLKAYVDEFKFQSILAEDFLEF 456
Cdd:cd09604 381 SKGALFLEELREELGD-EAFDKALREYYRRYKFKHPTPEDFFRT 423
GluZincin cd09594
Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, ...
272-351 1.34e-16

Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, M2, M3, M4, M13, M32 and M36 (fungalysins); The Gluzincin family (thermolysin-like peptidases or TLPs) includes several zinc-dependent metallopeptidases such as M1, M2, M3, M4, M13, M32, M36 peptidases (MEROPS classification), which contain the HEXXH motif as part of their active site. Peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. The M1 family includes aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity such that the two activities occupy different, but overlapping sites. The M3_like peptidases include the M2_ACE, M3 or neurolysin-like family (subfamilies M3B_PepF and M3A) and M32_Taq peptidases. The M2 peptidase angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that regulates blood pressure, thus ACE inhibitors are important for the treatment of hypertension. M3A includes thimet oligopeptidase (TOP; endopeptidase 3.4.24.15), neurolysin (3.4.24.16), and the mitochondrial intermediate peptidase; and M3B includes oligopeptidase F. The M32 family includes eukaryotic enzymes from protozoa Trypanosoma cruzi, a causative agent of Chagas' disease, and from Leishmania major, a parasite that causes leishmaniasis, making these enzymes attractive targets for drug development. The M4 family includes secreted protease thermolysin (EC 3.4.24.27), pseudolysin, aureolysin, and neutral protease as well as bacillolysin (EC 3.4.24.28) that degrade extracellular proteins and peptides for bacterial nutrition, especially prior to sporulation. Thermolysin is widely used as a nonspecific protease to obtain fragments for peptide sequencing as well as in production of the artificial sweetener aspartame. The M13 family includes neprilysin (EC 3.4.24.11) and endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), which fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity and are prime therapeutic targets for selective inhibition. The peptidase M36 fungalysin family includes endopeptidases from pathogenic fungi. Fungalysin hydrolyzes extracellular matrix proteins such as elastin and keratin. Aspergillus fumigatus causes the pulmonary disease aspergillosis by invading the lungs of immuno-compromised animals and secreting fungalysin that possibly breaks down proteinaceous structural barriers.


Pssm-ID: 341057 [Multi-domain]  Cd Length: 105  Bit Score: 75.60  E-value: 1.34e-16
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  272 GEKLFGPYVWGRYDLLFMPP---SFPFGGMENP-CLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTN-ANWGEFWLNE 346
Cdd:cd09594  16 GRTSFRYPVSPIYSLLVYPAyveVNAYNAMWIPsTNIFYGAGILDTLSGTIDVLAHELTHAFTGQFSNLmYSWSSGWLNE 95

                ....*
gi 2039143  347 GFTMY 351
Cdd:cd09594  96 GISDY 100
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
37-229 9.31e-13

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 66.98  E-value: 9.31e-13
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143     37 LHLHLDLRaelppgpgpgSRGLNGKATLELRCLlpEGASELRLDSHScLEVMAATLLrGQPGDqqqltEPVPFHTQPFSH 116
Cdd:pfam17900   7 LDLKIDLK----------NFTFSGSVTITLQLN--NATNVIVLHASD-LTIRSISLS-DEVTS-----DGVPADFTEDQK 67
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143    117 YGQALCVVFPKPCCAAERFRLELTYRVgegpgvcWLAPEQTA---------GKKKPFVYTQGQAVLNRAFFPCFDTPAVK 187
Cdd:pfam17900  68 DGEKLTIVLPETLNQTGPYTLEIEYSG-------ELNDSMTGfyrstytdnGEKKVLVTTQFEPTDARSAFPCFDEPSVK 140
                         170       180       190       200
                  ....*....|....*....|....*....|....*....|....*.
gi 2039143    188 CTYSALVEVPDGFTAV--MS--ASTWERRGPNKFFFQMSQPIPSYL 229
Cdd:pfam17900 141 ATFTISIIHPKDYTALsnMPviASEPLENGWVITTFEQTPKMSTYL 186
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
224-454 2.34e-12

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 69.47  E-value: 2.34e-12
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  224 PIPSYLIALAIGDLASAE---VGPRSRV------TEP-----------CLIEAAK--EEyngvieeflatgeklfgpyVW 281
Cdd:cd09600 174 PKPSYLFALVAGDLGSVEdtfTTKSGRKvklriyVEPgnedkchhameSLKKAMKwdEE-------------------RF 234
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  282 GR-YDL-LFM---PPSFPFGGMENPCLT-FVTPCLLAGDRSLAD--------VIIHEISHSWFGNLVTNANWGEFWLNEG 347
Cdd:cd09600 235 GLeYDLdLFNivaVDDFNMGAMENKGLNiFNSKYVLADPETATDadyeriesVIAHEYFHNWTGNRVTCRDWFQLSLKEG 314
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 2039143  348 FTMYAQRRISTILFGAAYTCLEAAtgrALLRQHM---DVSGEENPlnklrVKIEPGVDPDDTYNETPYEKGYCFVSYLAH 424
Cdd:cd09600 315 LTVFRDQEFSADMNSRAVKRIEDV---RRLRSAQfpeDAGPMAHP-----IRPDSYIEINNFYTVTVYEKGAEVIRMLHT 386
                       250       260       270
                ....*....|....*....|....*....|
gi 2039143  425 LVGDqEQFDKFLKAYVDEFKFQSILAEDFL 454
Cdd:cd09600 387 LLGE-EGFRKGMDLYFERHDGQAVTCEDFV 415
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH